If you are able to provide cardioprotection, then you will have anti-cancer synergy. The mechanisms of cardioprotection require greater concentrations of Bisantrene than anti-cancer. 79% of Oncolines cell lines at 500 nM, while meaningful cardioprotection at 1uM across a wide range of drugs. The difference between cardioprotection and synergy is that while some patients should benefit from the anti-cancer synergy, there should be significantly more that are protected from dox cardiotoxicity. Cancerous tissue is more dynamic and less predictable than non-canceroue tissues.
There are many ways to evaluate the combination efficacy in comparison to single agent Dox.
If you are able to provide cardioprotection, then you will have...
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.86 |
Change
-0.015(0.80%) |
Mkt cap ! $316.8M | |||
| Open | High | Low | Value | Volume |
| $1.88 | $1.88 | $1.79 | $163.0K | 89.00K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34299 | $1.84 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.86 | 3635 | 1 |
View Market Depth
| Last trade - 16.10pm 18/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |